Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:weapon
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Chiron_Corporation
gptkb:Upjohn |
| gptkbp:activities |
stimulates erythropoiesis
|
| gptkbp:approves |
gptkb:1990
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:clinical_trial |
Phase II
Phase III chronic kidney disease Phase I chemotherapy-induced anemia HIV-related anemia surgery-related anemia |
| gptkbp:contraindication |
pure red cell aplasia
uncontrolled hypertension hypersensitivity to epoetin alfa |
| gptkbp:current_use |
anemia of chronic disease
anemia due to HIV treatment anemia due to cancer treatment anemia due to renal failure |
| gptkbp:dosage_form |
injection solution
|
| gptkbp:formulation |
lyophilized powder
liquid solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Procrit
|
| gptkbp:ingredients |
gptkb:epoetin_alfa
|
| gptkbp:interacts_with |
iron supplements
antihypertensives other erythropoiesis-stimulating agents |
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
blood pressure
hemoglobin levels iron status |
| gptkbp:is_used_for |
gptkb:fandom
|
| gptkbp:manager |
subcutaneous injection
intravenous injection |
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:marketed_as |
gptkb:Epogen
gptkb:Eprex gptkb:Aranesp |
| gptkbp:packaging |
single-use vials
multi-dose vials |
| gptkbp:sales |
widely used in Europe
widely used in the US widely used in Canada |
| gptkbp:shelf_life |
36 months
|
| gptkbp:side_effect |
fatigue
headache nausea hypertension allergic reactions seizures thromboembolic events injection site reactions |
| gptkbp:storage |
refrigerated
|